Skip to main content

Table 1 Characteristics of patients in the training and validation series

From: Predicting a local recurrence after breast-conserving therapy by gene expression profiling

Characteristic Training Validation All
No. of patients 81 80 161
Non-local recurrence 72 (89%) 72 (90%) 144 (89%)
Local recurrence 9 (11%) 8 (10%) 17 (11%)
Tumor size T1/T2 50/31 (62%/38%) 48/32 (60%/40%) 98/63 (61%/39%)
pN0/pN+ 46/35 (57%/43%) 44/36 (55%/45%) 90/71 (56%/44%)
Grade I/II/III 22/26/33 (27%/32%/41%) 21/28/31 (26%/35%/39%) 43/54/64 (27%/33%/40%)
Age <40 years 62 (77%) 64 (80%) 126
Follow-up (years) 7.87 7.56 7.69
Metastasis 26 (32%) 23 (29%) 49 (30%)
Chemotherapy 28 (35%) 30 (38%) 58 (36%)
Hormonal therapy 10 (12%) 8 (10%) 18 (11%)
ER+/ER- 66/15 (81%/19%) 55/25 (69%/31%) 121/40 (75%/25%)
Median RT dose (Gy) 50 50 50
Median boost dose (Gy) 15 15 15
Boost, yes/no 70/11 (86%/16%) 74/6 (93%/7%) 144/17 (89%/11%)
Margins infiltrating carcinomaa 73, 4, 4 (90%, 5%, 5%) 72, 3, 5 (90%, 4%, 6%) 145, 7, 9 (90%, 4%, 6%)
Margins DCISb 25, 48, 3, 5 (31%, 59%, 4%, 6%) 27, 41, 7, 5 (34%, 51%, 9%, 6%) 52, 89, 10, 10 (33%, 55%, 6%, 6%)
  1. pN0, pathologically node negative; pN+, pathologically node positive; ER, estrogen receptor; RT, radiotherapy; DCIS, ductal carcinoma in situ.
  2. aResults are given in the following sequence: radical, focally positive resection margin, extensively positive resection margin or positive resection margin not otherwise specified; bresults are given in the following sequence: no DCIS, radical, focally positive resection margin, extensively positive resection margin or positive resection margin not otherwise specified.
\